Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581242 | 0.92 | TDP1 (0.59) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL28449486 | 0.92 | TDP1 (0.59) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL28985362 | 0.90 | MGLL (0.55) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL8008707 | 0.89 | MGLL (0.62) | TDP1L3MBTL1 | |
| SCHEMBL8008712 | 0.89 | MGLL (0.62) | TDP1L3MBTL1 | |
| SCHEMBL21457937 | 0.88 | GLS (0.50) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL21457938 | 0.88 | GLS (0.50) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL12664538 | 0.86 | MGLL (0.61) | TDP1L3MBTL1 | |
| SCHEMBL30958386 | 0.86 | MGLL (0.61) | TDP1L3MBTL1 | |
| SCHEMBL16882232 | 0.85 | TDP1 (0.53) | TDP1L3MBTL1CHRM2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313816-B1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2023-05-24 | — | — | EP | disclosed |